Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[PDF][PDF] Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the …
OP-EHEA191011_online 2313..2340 Page 1 Low-density lipoproteins cause atherosclerotic
cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus …
cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus …
Organic neuroelectronics: from neural interfaces to neuroprosthetics
Requirements and recent advances in research on organic neuroelectronics are outlined
herein. Neuroelectronics such as neural interfaces and neuroprosthetics provide a …
herein. Neuroelectronics such as neural interfaces and neuroprosthetics provide a …
[HTML][HTML] Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow …
Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and …
I Yakoub-Agha, C Chabannon, P Bader… - …, 2019 - pmc.ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which
autologous or allogeneic T cells are engineered to express a CAR targeting a membrane …
autologous or allogeneic T cells are engineered to express a CAR targeting a membrane …
COVID‐19‐related encephalopathy: a case series with brain FDG‐positron‐emission tomography/computed tomography findings
Aim The aim of this paper is to describe the clinical features of COVID‐19‐related
encephalopathy and their metabolic correlates using brain 2‐desoxy‐2‐fluoro‐D‐glucose …
encephalopathy and their metabolic correlates using brain 2‐desoxy‐2‐fluoro‐D‐glucose …
Cytokines in CAR T cell–associated neurotoxicity
Chimeric antigen receptor (CAR) T cells provide new therapeutic options for patients with
relapsed/refractory hematologic malignancies. However, neurotoxicity is a frequent, and …
relapsed/refractory hematologic malignancies. However, neurotoxicity is a frequent, and …
Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
RC Sterner, RM Sterner - Frontiers in immunology, 2022 - frontiersin.org
Chimeric antigen receptor (CAR)-T cell therapy is an emerging staple in the treatment of
certain hematological malignancies. While CAR-T cells have produced robust responses in …
certain hematological malignancies. While CAR-T cells have produced robust responses in …
Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis
C-type lectin-like molecule-1 (CLL1) is preferentially expressed on acute myeloid leukemia
(AML) stem cells and AML blasts, which can be considered as AML-associated antigen. Anti …
(AML) stem cells and AML blasts, which can be considered as AML-associated antigen. Anti …
Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a …
Chimeric antigen receptor (CAR) T cell therapy is a novel therapy for patients with relapsed
or refractory hematologic malignancies. Most CAR T cell therapy recipients will experience …
or refractory hematologic malignancies. Most CAR T cell therapy recipients will experience …
CAR T-cell therapy for patients with multiple myeloma: current evidence and challenges
The therapeutic landscape of multiple myeloma (MM) has benefited from an emergence of
novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric …
novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric …